Key Takeaways:
Complex biologics now define the development pipeline, with nearly 1,400 investigational antibody candidates in clinical study and bispecifics, multispecifics, and antibody-drug conjugates accounting for a growing share of them.1 These molecules raise the demands of cell line development, from achieving the correct ratios of the DNA chains that assemble each product to preserving the post-translational modifications that determine how it functions. For sponsors advancing them, two of the earliest decisions, how to build the cell line and how to make clinical material, tend to be handled as separate conversations on separate timelines. That separation invites comparability risk and lost time on the way to IND, because each choice constrains the other.
A production cell line carries every downstream process forward, so instability that appears early becomes a problem late. Chinese hamster ovary (CHO) cells are prized for their productivity, yet their plastic genome makes them prone to titer and product-quality drift over extended culture.2 Random integration compounds the risk by placing genes anywhere in the genome, including truncated or concatemerized configurations that lead to rearrangement or silencing, which is why stability studies at 30, 60, and 90 generations became standard practice.
Semi-targeted integration with transposase technology takes a different route, inserting complete expression cassettes into open, transcriptionally active chromatin, which favors cell lines that are both stable and highly expressing. This foundation proves its value at tech transfer, where reduced pool-to-clone variability lets teams commit to a candidate earlier and move into process development sooner, especially when high-throughput screening evaluates thousands of clones rather than a few hundred.
The manufacturing model chosen during development shapes how much flexibility a program keeps as it advances. Traditional scale-up moves a process through progressively larger stainless-steel vessels, and each increase in scale changes mixing, gas transfer, and other culture conditions in ways that can affect product quality and reproducibility.
Single-use, scale-out manufacturing removes those scale transitions by maintaining one vessel size and adding bioreactors in parallel as output needs grow. Keeping the conditions consistent protects product quality from development through commercial supply. It also allows for launch at clinical scale, with capacity added as demand becomes clear, rather than a commitment to fixed infrastructure before approval. That flexibility becomes an advantage in a development environment where demand forecasts are unreliable, large-scale readiness is expensive to build ahead of need, and accelerated regulatory pathways can pull timelines forward with little warning. Capital then tracks real demand instead of a projection.
Considered as one strategy, a flexible expression platform and a flexible manufacturing model work in tandem to drive programs to IND. A stable, consistent cell line reduces the product-quality surprises that complicate tech transfer, and single-use scale-out avoids the comparability studies that a move to larger vessels would require. Standardized single-use equipment also makes transfer between sites more straightforward if a program needs to relocate work or add capacity. Together these choices compress timelines and preserve capital at the two points where programs most often stall, cell line stability and manufacturing scale-up. That is difficult to orchestrate across two vendors working to different clocks, and far more achievable with a single partner executing both.
Figure 1. Two paths to IND. Deciding cell line development and manufacturing strategy separately (left) versus together and early (right).
The highest-leverage moment to align these choices comes at candidate selection, before either the cell line or the manufacturing path is fixed. Engaging a CDMO that executes both well at that stage lets the platform and capacity adapt to the molecule rather than the reverse, and it leaves room to define a fallback plan should a candidate underperform. AGC Biologics supports sponsors across the full path from DNA to IND-enabling and clinical manufacturing, pairing semi-targeted integration for cell line development with single-use, scale-out manufacturing, all the way through drug product filling. To talk through an integrated strategy for your program, contact us.
References:
Crescioli S, Kaplon H, Wang L, Visweswaraiah J, Kapoor V, Reichert JM. Antibodies to watch in 2025. MAbs. 2025;17(1):2443538. doi:10.1080/19420862.2024.2443538
Dahodwala H, Lee KH. The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Curr Opin Biotechnol. 2019;60:128-137. doi:10.1016/j.copbio.2019.01.011